Kinesins are motor proteins that convert the chemical energy of ATP into mechanical energy and move along microtubules and play various physiological roles. Eg5 is a homotetrameric protein that belongs to the kinesin-5 family. It plays an important role in separating and the formation of bipolar spindles during mitosis cell division. Eg5 is overexpressed in proliferative tissues, and specific inhibition of Eg5 has been shown to induce apoptosis in cancer cells, making it an attractive target part for cancer therapy. Eg5 has specific inhibitors such as Monastrol and STLC, and these are attracting attention as anticancer agents. In our laboratory, previously we synthesized a photochromic Eg5 inhibitor with a photoswitch mechanism by introducing a photoresponsive compound such as azobenzene into a specific Eg5 inhibitor. In this study so far, by coupling of azobenzene and spiropyran, we synthesized an Eg5 inhibitor that introduced a novel photochromic compound that transitions into three different states by light, and photoreversibly controlled the function of Eg5 in three states. In this study, we conducted in vivo experiments to stepwise and appropriately regulated the physiological functions of Eg5. We have attempted to develop new inhibitors that exhibit multi-stage inhibitory activity. Finally, we clarified which steps of the Eg5-ATPase cycle are inhibited by azobenzene and spiropyran derivatives by the mixed motor assays and analyzed the kinetic inhibition mechanisms of Eg5 inhibitors by azobenzene-spiropyran derivatives.